From conventional to stealth liposomes: a new Frontier in cancer chemotherapy
- PMID: 15688621
- DOI: 10.1179/joc.2004.16.Supplement-1.94
From conventional to stealth liposomes: a new Frontier in cancer chemotherapy
Abstract
In this review, the different types of liposome used in medicine, in particular in the field of antitumor therapy, are focalised, emphasizing their structures, pharmacological action, pharmacokinetics and biodistribution, toxicity profiles and in the main clinical applications. The first-generation liposomes (conventional liposomes) comprised a liposome-containing amphotericin B, Ambisome, and Myocet, doxorubicin-containing liposome used in clinical trials to treat metastatic breast cancer. The last generation liposomes were pegylated liposomal doxorubicin (Caelix), called "stealth liposomes" because of their ability to evade interception by the immune system, characterized by very long-circulation half-life, favourable pharmacokinetic behaviour and specific accumulation in tumor tissues.
Similar articles
-
From conventional to stealth liposomes: a new frontier in cancer chemotherapy.Tumori. 2003 May-Jun;89(3):237-49. doi: 10.1177/030089160308900302. Tumori. 2003. PMID: 12908776 Review.
-
Development of stealth liposome coencapsulating doxorubicin and fluoxetine.J Liposome Res. 2011 Dec;21(4):261-71. doi: 10.3109/08982104.2010.545070. Epub 2011 Jan 12. J Liposome Res. 2011. PMID: 21226547
-
Selective delivery of doxorubicin to patients with breast carcinoma metastases by stealth liposomes.Cancer. 1999 Jul 1;86(1):72-8. Cancer. 1999. PMID: 10391566
-
Estrogen-anchored pH-sensitive liposomes as nanomodule designed for site-specific delivery of doxorubicin in breast cancer therapy.Mol Pharm. 2012 Jan 1;9(1):176-86. doi: 10.1021/mp200439z. Epub 2011 Nov 28. Mol Pharm. 2012. PMID: 22091702
-
Liposomal anticancer therapy: pharmacokinetic and clinical aspects.J Chemother. 2004 Nov;16 Suppl 4:90-3. doi: 10.1179/joc.2004.16.Supplement-1.90. J Chemother. 2004. PMID: 15688620 Review.
Cited by
-
Cell delivery of therapeutic nanoparticles.Prog Mol Biol Transl Sci. 2011;104:563-601. doi: 10.1016/B978-0-12-416020-0.00014-0. Prog Mol Biol Transl Sci. 2011. PMID: 22093229 Free PMC article.
-
A systemically administered detoxified TLR4 agonist displays potent antitumor activity and an acceptable tolerance profile in preclinical models.Front Immunol. 2023 May 8;14:1066402. doi: 10.3389/fimmu.2023.1066402. eCollection 2023. Front Immunol. 2023. PMID: 37223101 Free PMC article.
-
In vitro evaluation of theranostic polymeric micelles for imaging and drug delivery in cancer.Theranostics. 2012;2(7):714-22. doi: 10.7150/thno.3927. Epub 2012 Jul 31. Theranostics. 2012. PMID: 22896773 Free PMC article.
-
Liposomal vincristine for relapsed or refractory Ph-negative acute lymphoblastic leukemia: a review of literature.Ther Adv Hematol. 2014 Feb;5(1):18-24. doi: 10.1177/2040620713519016. Ther Adv Hematol. 2014. PMID: 24490021 Free PMC article. Review.
-
Antibody-Nanoparticle Conjugates in Therapy: Combining the Best of Two Worlds.Small. 2025 Apr;21(15):e2409635. doi: 10.1002/smll.202409635. Epub 2025 Mar 6. Small. 2025. PMID: 40051146 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources